Phathom Pharmaceuticals Inc PHAT Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Socks David A

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-20,091

Price:

$36.18
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Socks David A

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-7,074

Price:

$35.74
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Socks David A

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-12,835

Price:

$34.92
Dec 17, 2020 (filed on Dec 18, 2020)

Insider Name:

Socks David A

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-100

Price:

$42.00
Dec 17, 2020 (filed on Dec 18, 2020)

Insider Name:

Socks David A

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-12,915

Price:

$41.43
Dec 17, 2020 (filed on Dec 18, 2020)

Insider Name:

Socks David A

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-35,197

Price:

$40.49
Dec 16, 2020 (filed on Dec 18, 2020)

Insider Name:

Socks David A

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-200

Price:

$48.99
Dec 16, 2020 (filed on Dec 18, 2020)

Insider Name:

Socks David A

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-12,954

Price:

$48.19
Dec 16, 2020 (filed on Dec 18, 2020)

Insider Name:

Socks David A

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-13,292

Price:

$47.35
Dec 16, 2020 (filed on Dec 18, 2020)

Insider Name:

Socks David A

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-5,000

Price:

$46.22

Filings by filing date

Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Socks David A

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-20,091

Price:

$36.18
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Socks David A

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-7,074

Price:

$35.74
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Socks David A

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-12,835

Price:

$34.92
Jan 05, 2020 (filed on Jan 05, 2021)

Insider Name:

Nabulsi Azmi

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,854

Price:

$33.77
Jan 04, 2020 (filed on Jan 05, 2021)

Insider Name:

Nabulsi Azmi

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-100

Price:

$34.57
Jan 04, 2020 (filed on Jan 05, 2021)

Insider Name:

Nabulsi Azmi

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-7,614

Price:

$33.93
Jan 04, 2020 (filed on Jan 05, 2021)

Insider Name:

Nabulsi Azmi

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-4,932

Price:

$33.02
Dec 17, 2020 (filed on Dec 18, 2020)

Insider Name:

Socks David A

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-100

Price:

$42.00
Dec 17, 2020 (filed on Dec 18, 2020)

Insider Name:

Socks David A

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-12,915

Price:

$41.43
Dec 17, 2020 (filed on Dec 18, 2020)

Insider Name:

Socks David A

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-35,197

Price:

$40.49

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	100 CAMPUS DRIVE,, SUITE 102 FLORHAM PARK NJ 07932
Tel:	N/A
Website:	https://www.phathompharma.com
IR:	See website

Key People

Tadataka Yamada Independent Chairman of the Board	Terrie J. Curran President, Chief Executive Officer, Director	David Socks Co-Founder, Chief Financial Officer, Treasurer, Director
Azmi Nabulsi Co-Founder, Chief Operating Officer	Aditya Kohli Chief Business Officer and Co-founder

Business Overview

Phathom Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing treatments for gastrointestinal (GI) diseases. Its product candidate, vonoprazan, is an oral small molecule potassium competitive acid blocker (P-CAB). It is developing vonoprazan as an agent in the treatment of gastroesophageal reflux disease (GERD) and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. Vonoprazan accumulates in the secretory canaliculus where the proton pumps are present in their active state. Vonoprazan binds to proton pumps in both their inactive and active states and remains in the secretory canaliculus where it continues to inhibit acid secretion over an extended period.

Financial Overview

For the nine months ended 30 September 2020, PhathomPharmaceuticals Inc revenues was not reported. Net lossdecreased 52% to $75.3M. Lower net loss reflects In-processresearch and development decrease from $78.9M (expense) to$0K, Change in fair value of warrant liabilit increase from$59.1M (expense) to $95K (income), Change in fair value ofconvertible prom decrease from $4.9M (expense) to $0K.

Employees:	25 as of Dec 31, 2019

Reporting Currency:	U.S. Dollars
Enterprise value:	$1,014M as of Sep 30, 2020
Annual revenue (TTM):	$0.00M as of Sep 30, 2020
EBITDA (TTM):	-$88.70M as of Sep 30, 2020
Net annual income (TTM):	-$173.35M as of Sep 30, 2020
Free cash flow (TTM):	-$65.89M as of Sep 30, 2020
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	28,964,506 as of Nov 6, 2020
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

INK Ultra Money Free

INK Ultra Money Videos

Phathom Pharmaceuticals Inc (OQ:PHAT)